Revelation Biosciences, Inc. Warrant (REVBW) Stock Price
REVBWStock
$0.01
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta3.45
REVBW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-7.04%
Price vs S&P 500 (4W)49.26%
VGM Score16.85
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
REVBWRevelation Biosciences, Inc. Warrant | — | — | F | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Revelation Biosciences, Inc. Warrant
Revelation Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of immunotherapy products based on Gemini, its proprietary TLR4 agonist formulation designed to harness the body's innate immune response to treat inflammatory diseases. The company is advancing three Gemini-based candidates targeting high-value indications: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.